Background to the development of steroid sulphatase inhibitors
It is now generally accepted that the in situ formation of oestrogens in breast tumours, and also possibly in endometrial tumours, makes a major contribution to the high oestrogen concentrations found in these tissues (Naitoh etal. 1989 , Reed etal. 1989 ). Concen¬ trations of the biologically active oestrogen oestradiol are higher than those of oestrone in tumours, and levels of both oestrogens in tumours are considerably higher than the low plasma oestrogen concentrations that are found in postmenopausal women (Bonney et al. 1983 , Van Landeghem et al. 1985) . Although breast and endometrial cancer occur in premenopausal women, the highest incidence is in postmenopausal women, at a time when ovarian production of oestrogen has ceased. Oestrogens continue to be produced in postmenopausal women and, while adipose tissue is a major site of peripheral oestrogen synthesis, all the enzymes which are required for oestrogen formation from androgen precursors are present in breast tumours (James et al. 1987 ).
The enzymes that are involved in breast tumour oestrogen synthesis are shown in Fig. 1 . The enzymes are aromatase, which converts androstenedione to oestrone ( Fig. 2(1) ), and oestradiol 17ß-hydroxysteroid dehydrogenase, which in breast tumours converts oestrone to oestradiol (McNeill et al. 1986 , Luu-The et al. 1989 ). Much of the oestrone formed from androstenedione is metabolised to oestrone sulphate ( Fig. 2(2) ) by oestrone sulphotransferase (Hobkirk 1993) , and can be converted back to oestrone by the action of oestrone sulphatase.
Plasma concentrations of oestrone sulphate are 10-20 times higher than those of the unconjugated oestrogens (Noel et al. 1981) , and the half-life of oestrone sulphate in blood (10-12 h) is considerably longer than that of unconjugated oestrogens (20 min) (Ruder et al. 1972) . Furthermore (Johnston et al. 1994 , Svenstrup et al. 1994 , and it was reasoned that conversion of oestrone sulphate to oestrone and oestradiol was the likely source of the unconjugated oestrogens which were still detectable in the plasma of women receiving aromatase inhibitor therapy . The results from these clinical studies prompted the synthesis of the first steroid sulphatase inhibitor, oestrone-3-O-methylthiophosphonate (El-MTP, Fig. 2(3) The origin of androstenediol has been investi¬ gated using isotopie infusion techniques, similar to those used to measure in vivo peripheral aromatase activity (Poortman etal. 1980 ). More than 90% of the androstenediol produced in postmenopausal women was found to originate from DHEA-S. DHEA-S can either be converted to DHEA by DHEA sulphatase, with subsequent metabolism of DHEA to androst¬ enediol, or converted to androstenediol sulphate, with subsequent hydrolysis to androstenediol (Fig.  1 ) . Although the affinity of androstenediol for the ER is somewhat lower than that of oestradiol, plasma androstenediol concentrations are 100-fold higher than those of oestradiol. A significant correlation was also found between plasma DHEA-S and androstenediol concentrations in postmenopausal women, adding further evidence for DHEA-S being the major source of plasma androstenediol (Bonney etal. 1984 (Reed & Purohit 1994 (Tseng etal. 1983 ).
Increased oestrone sulphatase activity in endometrial cancer tissue has also been detected (Yamamoto et al. 1993 Oestrone-3-O-methyhhiophosphonate
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3-Methyl-1 -pentafluorophenylmethyl-6-sulphooxy-2-(4-sulphooxyphenyl)-4-trifluoromethylindole, disodium salt (14) 5,6,7,8-tetrahydronaphth-3-0-sulphamate (THN-sulphamate) (15) production of cytokines by these cells, however, it is now apparent that infiltration of breast tumours by macrophages and lymphocytes is an additional important source of cytokine production (Purohit et al. 1995 ) .
Endocrine drugs as potential steroid sulphatase inhibitors As previously discussed, danazol was the first drug which, in addition to its other properties, was also found to inhibit steroid sulphatase (Carlstrom et al. 1984 ) . In a preliminary study the effect of danazol therapy (800 mg/day for 2 weeks) on the conversion ratio (CR) of oestrone sulphate to oestrone was investigated in three menopausal women with breast cancer (Purohit et al. 1992 ). For two of the three women, a 40% decrease in the CR was detected, while no change occurred in the third subject. Sulphatase activity in normal breast tissue obtained from these women decreased by 24-64% and there was a 31% decrease in plasma oestrone concentra¬ tions. From this investigation it was concluded that, while danazol could inhibit steroid sulphatase activity in vivo, it was a relatively weak inhibitor.
The ability of danazol to inhibit oestrone sulphatase activity has also been examined using breast cancer cell lines which possess oestrone sulphatase activity. Using cell homogenates, danazol (10 µ ) inhibited oestrone sulphatase activity (measured using a substrate concentration of 8 µ )
in MCF-7 cells by 38%, in MDA-MB-231 cells by 36% and in T47D cells by 27% (Nguyen et al. 1993 ). In intact MCF-7 breast cancer cells, using a physio¬ logical substrate concentration (2 nM), danazol (10 µ ) inhibited sulphatase activity by 62% (Purohit & Reed 1992 Santner & Santen (1993) , such an effect is likely to be secondary to their ability to bind to the ER and block the action of oestradiol.
In view of the results of a number of investiga¬ tions suggesting that antioestrogens may possess steroid sulphatase inhibitory properties, a study was carried out to examine their effects in vivo on rat liver steroid sulphatase activity (Purohit etal. 1995c (Soderqvist etal. 1994 (Pasqualini etal. 1994 Fig. 2(4) ). In contrast oestrone-3-0-(/V,/Vdimethyl)sulphamate (DEMATE, Fig. 2(6) ) and oestrone-3-O-methylthiophosphonate (E1-MTP, Fig. 2(3 Fig. 2(4) ), and its /V-methylated derivatives (Fig. 2(5/6) ), emerged as being extremely potent (Table 1) . EMATE (Fig. 2(4) (Fig. 2(5) ) and N,Ndimethylated derivatives (Fig. 2(6) (Fig. 2(7) ) derivative of oestrone was a rela¬ tively strong inhibitor, inhibiting oestrone sulphatase activity in placental microsomes by 65% at 60 µ . The series of potential sulphatase inhibitors tested by these researchers has now been extended to include desoxyoestrone-3-sulphonylfluoride (Fig. 2(8) ) and desoxyoestrone-3-sulphonylamide (Fig. 2(9) ). In this series, the contribution of distinctive sulphate ester groups and related 3-substituents on enzyme inhibition was examined (Dibbelt et al. 1994 (Fig. 2(10a) ) has also been synthesized and tested for its oestrone sulphatase inhibitory proper- (Fig. 2(11) ) and oestrone-3-methylene sulphonate (Fig. 2(12 (1990) and were based upon a new class of mammary tumour inhibitory compounds including 5-acetoxy-3-(4-acetoxypheny1)-1 -ethyl-3-methylindóle. The most potent inhibitor proved to be 3-methyl-lpentafluorophenylmethyl-6-sulphooxy-2-(4-sulphooxyphenyl)-4-trifluoromethylindóle (Fig.  2(14) ). Using a partially purified steroid sulphatase prepared from calf uterus, this compound had an IC50 of80pM.
In order to explore the structure-activity relation¬ ship of different types of steroid sulphatase inhibitors, and also to examine the possibility of developing a non-steroidal inhibitor, a series of sulphamate derivatives of tetrahydronaphthol ( ) (Fig. 2(15-17) ) and diethylstilboestrol (DES) (Fig.  2(18/19) ) was synthesized and these were tested for their ability to inhibit oestrone sulphatase (Table 2 ).
Three sulphamate derivatives of were synthesized. Of these the iV,N-dimethylsulphamate ( Fig. 2(17) ) was inactive when tested at 10 µ , with THN-sulphamate ( Fig. 2(15) Table 2 . Like EMATE, DES-bis-sulphamate (Fig.  2(18) ) appears to act as an irreversible inhibitor. While further research is currently in progress to develop a non-steroidal non-oestrogenic inhibitor which is equipotent with EMATE, the finding that phenolic compounds other than steroids can be utilized for the development of potent inhibitors should greatly facilitate the search for a non-steroidal inhibitor. This had led to the development of a series of coumarin sulphamate derivatives which are nonoestrogenic but which have similar inhibitory prop¬ erties to those of EMATE (Woo et Selcer & Li (1995) investigated their effects on the growth of the rat uterus in ovariectomized animals. These compounds were found to be well tolerated in vivo at up to 100 pg/day. Neither 3-amino-nor 3-thio-oestrone had any effect on uterine weight when tested at 25 µg/day, indicating that they were not oestrogenic. These (Purohit et al. 1995c (Wilkinson et al. 1986) , and Santner et al. (1990) (Purohit etal. 1995c Fig. 2(20) ) and the 3-/V-sulphamate ( Fig. 2(21) ), not only reduces the potency of EMATE as an inhibitor, but also abol¬ ishes its active site-directed mode of inhibition (Woo etal. 1996a 
